Insulin Glargine News and Research

RSS

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announced today that the U.S. Food and Drug Administration approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2 2015.

26 Feb 2015

Study clarifies association between metformin use and lung cancer risk

Among nonsmokers who had diabetes, those who took the diabetes drug metformin had a decrease in lung cancer risk, according to a study in Cancer Prevention Research, a journal of the American Association for Cancer Research, by Lori Sakoda, PhD, MPH, research scientist at the Kaiser Permanente Division of Research in Oakland, California.

2 Feb 2015

Lilly and Boehringer Ingelheim's insulin glargine product gets marketing approval from EC

The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above.

10 Sep 2014

Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection) gets FDA's tentative approval

The U.S. Food and Drug Administration today granted tentative approval for Basaglar (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes.

19 Aug 2014

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Adocia announces today positive final results for the first clinical trial on its innovative formulation combining insulin analog glargine (Lantus, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, lispro (Humalog, Eli Lilly) using Adocia's BioChaperone technology.

20 Mar 2014

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Adocia announces today positive preliminary results for the first clinical trial on an innovative formulation combining insulin analog Glargine (Lantus, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, Lispro (Humalog, Eli Lilly) using Adocia's BioChaperone technology.

27 Feb 2014

Merck, Samsung Bioepis agree to develop, commercialize MK-1293 for treatment of diabetes

Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.

10 Feb 2014

Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Eli Lilly and Company and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration has accepted the filing of the New Drug Application for LY2963016, an investigational basal (long-acting) insulin.

21 Dec 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia—low blood sugar—compared with the commercially available insulin glargine, a new meta-analysis study finds.

19 Jun 2013

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.

18 Apr 2013

Insulin degludec shows promise in diabetes

Self-administration of daily insulin degludag injections is no less effective than self-injecting insulin glargine in patients with diabetes who are new to insulin therapy, say researchers.

4 Oct 2012

Boehringer Ingelheim, Lilly announce data from LY2605541 Phase II study on type 2 diabetes

Eli Lilly and Company and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes.

3 Oct 2012

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.

27 Sep 2012

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Biodel Inc. today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123.

13 Sep 2012

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

27 Aug 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Degludec reduces risk of nighttime low blood sugar in elderly diabetic adults

A new variety of long-lasting insulin, called insulin degludec, lowers the risk of nighttime low blood sugar in elderly diabetic adults compared with insulin glargine, a systematic review of diabetes studies has found.

26 Jun 2012

Insulin more effective add-on than sitagliptin in glucose control

Insulin seems to be a more effective add-on regimen than sitagliptin in patients with diabetes inadequately controlled by metformin monotherapy, show study findings.

15 Jun 2012

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.